A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants

September 30, 2026 updated by: Bristol-Myers Squibb

A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants

The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
80

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: First line of the email MUST contain NCT # and Site #.

Study Contact Backup

  • Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  • Phone Number: 855-907-3286
  • Email: Clinical.Trials@bms.com

Study Locations

  • Canada
    • Quebec
      • Québec, Quebec, Canada, G1P 0A2
        • Recruiting
        • Syneos Health Clinique; Inc.
        • Contact:
          • Lidia Facchinelli, Site 0001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria

  • Participants must be healthy adult female (as assigned at birth) individuals not of childbearing potential (INOCBP) who have no clinically significant findings on medical history, physical examination (PE), vital signs (VS), 12-lead electrocardiograms (ECGs), or clinical laboratory determinations, as assessed by the investigator.
  • Participants must have a BMI of 18.0 to 35.0 kg/m2, inclusive.

Exclusion Criteria

  • Participants must not have any significant acute or chronic medical illness (in the assessment of the investigator).
  • Participants must not have a history of prolonged bleeding or excessive bruising.
  • Participants must not have any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Part 2
Drug: Navlimetostat

Specified dose on specified days

Other Names:
  • BMS-986504
  • MRTX-1719
Drug: Midazolam

Specified dose on specified days
Experimental: Part 3
Drug: Navlimetostat

Specified dose on specified days

Other Names:
  • BMS-986504
  • MRTX-1719
Experimental: Part 1A
Drug: Navlimetostat

Specified dose on specified days

Other Names:
  • BMS-986504
  • MRTX-1719
Drug: Itraconazole

Specified dose on specified days
Experimental: Part 1B
Drug: Navlimetostat

Specified dose on specified days

Other Names:
  • BMS-986504
  • MRTX-1719
Drug: Rifampin

Specified dose on specified days
Experimental: Part 4
Drug: Navlimetostat

Specified dose on specified days

Other Names:
  • BMS-986504
  • MRTX-1719
Drug: Pantoprazole

Specified dose on specified days

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Drug-related AEs
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Maximum observed concentration (Cmax) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A, Part 1B, Part 3, Part 4
Up to approximately 3 weeks
Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A
Up to approximately 3 weeks
(AUC(INF)) of Navlimetostat with the coadministration of itraconazole
Time Frame: Up to approximately 3 weeks

Part 1A
Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of itraconazole
Time Frame: Up to approximately 3 weeks

Part 1A
Up to approximately 3 weeks
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1B, Part 3, Part 4
Up to approximately 3 weeks
AUC(INF) of Navlimetostat with the coadministration of Rifampin
Time Frame: Up to approximately 3 weeks

Part 1B
Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of Rifampin
Time Frame: Up to approximately 3 weeks

Part 1B
Up to approximately 3 weeks
Cmax of Midazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(0-T) of Midazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(INF) of Midazolam with the coadministration of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(INF) of Midazolam without the coadministration of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(INF) of Navlimetostat with a high fat meal
Time Frame: Up to approximately 3 weeks

Part 3
Up to approximately 3 weeks
AUC(INF) of Navlimetostat without a high fat meal
Time Frame: Up to approximately 3 weeks

Part 3
Up to approximately 3 weeks
AUC(INF) of Navlimetostat with the coadministration of Pantoprazole
Time Frame: Up to approximately 3 weeks

Part 4
Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of Pantoprazole
Time Frame: Up to approximately 3 weeks

Part 4
Up to approximately 3 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Adverse events (AEs)
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Serious adverse events (SAEs)
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
AEs leading to discontinuation of study or study intervention
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Number of participants with clinically significant changes in physical examination (PE)
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Number of participants with clinically significant changes in vital signs (VS)
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Number of participants with clinically significant changes in 12-lead electrocardiograms (ECGs)
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Number of participants with clinically significant changes in clinical laboratory test results
Time Frame: Up to approximately 6 weeks
Up to approximately 6 weeks
Cmax of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
AUC(0-T) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
AUC(INF) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
Tmax of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
T-HALF of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
Mean ratio (MR)_Cmax of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
MR_AUC(0-T) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
MR_AUC(INF) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks
Up to approximately 3 weeks
AUC(0-T) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A
Up to approximately 3 weeks
Time of maximum observed concentration (Tmax) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A, Part 1B, Part 3, Part 4
Up to approximately 3 weeks
Half-life (T-HALF) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A, Part 1B, Part 3, Part 4
Up to approximately 3 weeks
Apparent total body clearance (CLT/F) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A, Part 1B, Part 3, Part 4
Up to approximately 3 weeks
Apparent volume of distribution at terminal phase (Vz/F) of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 1A, Part 1B, Part 3, Part 4
Up to approximately 3 weeks
Tmax of Midazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
T-HALF of Midazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
CLT/F of Midazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
Vz/F of Midazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(0-192) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks

Part 1A
Up to approximately 3 weeks
AUC(0-24) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
MR_AUC(0-192) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks

Part 1A
Up to approximately 3 weeks
MR_AUC(0-24) of Navlimetostat Metabolite
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
Cmax of Rifampin
Time Frame: Up to approximately 3 weeks

Part 1A and Part 1B
Up to approximately 3 weeks
Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of Rifampin
Time Frame: Up to approximately 3 weeks

Part 1A and Part 1B
Up to approximately 3 weeks
Trough observed concentration (Ctrough) of Rifampin
Time Frame: Up to approximately 3 weeks

Part 1A and Part 1B
Up to approximately 3 weeks
Tmax of Rifampin
Time Frame: Up to approximately 3 weeks

Part 1A and Part 1B
Up to approximately 3 weeks
Cmax of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(0-T) of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
AUC(INF) of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
Tmax of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
T-HALF of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
MR_Cmax of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
MR_AUC(0-T) of 1-hydroxymidazolam
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
MR_AUC(INF) of 1-hydroxymidazolam with the coadministration of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks
MR_AUC(INF) of 1-hydroxymidazolam without the coadministration of Navlimetostat
Time Frame: Up to approximately 3 weeks

Part 2
Up to approximately 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 31, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 25, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 25, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 28, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 28, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 2, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 30, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA240-0050

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

IPD Sharing Time Frame

See Plan Description

IPD Sharing Access Criteria

See Plan Description

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings